Viridian Therapeutics’ eye disorder drug meets late-stage study goal

(Reuters) – Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)